SBIR Phase II: Biomolecular Cell Injection With Nanofountain Probe Systems

SBIR II 期：使用 Nanofountain 探针系统进行生物分子细胞注射

• 批准号: 1330151
• 负责人: Rebecca McNaughton
• 金额: $ 47.51万
• 依托单位: INFINITESIMAL LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-01 至 2016-02-29
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1330151&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Biomolecular; Cell

This Small Business Innovation Research (SBIR) Phase II project is aimed at increasing the throughput of a novel single-cell technology based on nanofountain probe electroporation (NFP-E). Progress in biotechnology research in recent years has shown promise for cell reprogramming and extremely sensitive medical diagnostics, yet this research requires effective, precise, and gentle transfection of cells - for which a robust tool is currently lacking. The NFP-E technology is capable of filling this need by enabling single-cell electroporation for dosage-controlled transport of biomolecules, proteins, or drugs into a cell. By applying a low electric potential to a target cell, small pores in the cell membrane are generated, which allows for delivery of molecules into cells in a way that is more efficient and less invasive than any other method of transfection used today. This proposed project has three primary goals: to establish protocols for various cell types and transfection agents, to fabricate a microwell plate that couples with the NFP-E, and to develop software algorithms to automate alignment and electroporation control. These developments will create a robust system with exceptional process control and cell viability that is suitable for relatively high throughput single-cell transfection applications.The broader impact/commercial potential of this project stems from the unprecedented capabilities that the novel tool will provide to researchers and biotechnology companies for manipulation and interrogation of cellular processes, benefiting fundamental biology research and the development of personalized medicine applications. This project will enhance the scientific and technological understanding of fundamental electroporation mechanisms and single cell analysis techniques by combining nanofabrication, microfluidics, biophysics, and molecular biology aspects. The NFP-E tool will allow scientists to use primary cells for research applications, providing a more meaningful link between laboratory research and human disease pathophysiology. In addition, this new tool could make the promise of personalized medicine feasible and practical by enabling new capabilities in biotechnology and providing a robust commercial instrument for single-cell studies toward discoveries that elucidate disease mechanisms, focus drug discovery efforts, and personalize disease diagnosis and therapies.

该小型企业创新研究 (SBIR) 第二阶段项目旨在提高基于纳米喷泉探针电穿孔 (NFP-E) 的新型单细胞技术的通量。近年来生物技术研究的进展显示出细胞重编程和极其灵敏的医学诊断的希望，但这项研究需要有效、精确和温和的细胞转染——目前缺乏强大的工具。 NFP-E 技术能够通过单细胞电穿孔以剂量控制的方式将生物分子、蛋白质或药物转运到细胞中来满足这一需求。通过对靶细胞施加低电势，细胞膜上会产生小孔，从而可以比当今使用的任何其他转染方法更有效且侵入性更小，从而将分子递送到细胞中。该项目有三个主要目标：为各种细胞类型和转染剂建立方案，制造与 NFP-E 耦合的微孔板，以及开发软件算法以自动对齐和电穿孔控制。这些发展将创建一个强大的系统，具有出色的过程控制和细胞活力，适用于相对高通量的单细胞转染应用。该项目更广泛的影响/商业潜力源于该新工具将为研究人员和研究人员提供前所未有的功能。生物技术公司对细胞过程进行操纵和询问，有利于基础生物学研究和个性化医疗应用的开发。该项目将通过结合纳米制造、微流体、生物物理学和分子生物学方面，增强对基本电穿孔机制和单细胞分析技术的科学和技术理解。 NFP-E 工具将使科学家能够将原代细胞用于研究应用，在实验室研究和人类疾病病理生理学之间提供更有意义的联系。此外，这种新工具可以通过启用生物技术的新功能并为单细胞研究提供强大的商业工具来实现个性化医疗的承诺，从而阐明疾病机制，集中药物发现工作以及个性化疾病诊断和治疗。疗法。